GLP-1 Agonists: A Head-to-Head Comparison for Weight Loss and Safety

Obesity is a global health crisis linked to numerous comorbidities like type 2 diabetes and cardiovascular disease. GLP-1 receptor agonists (GLP-1 RAs) have emerged as highly effective medications for weight reduction and glycemic control. However, with several GLP-1 RAs now available, clinicians and patients lack a comprehensive, direct comparison of their efficacy and safety profiles across different trials. This study addresses this critical gap by synthesizing data from multiple placebo-controlled trials to provide a comparative analysis of various GLP-1 receptor agonists for weight management.

The meta-analysis revealed significant and varying degrees of weight reduction among the different GLP-1 RAs. Semaglutide at its highest dose (2.4 mg weekly) demonstrated substantial efficacy, leading to a mean body weight reduction of 15.3% from baseline compared to placebo, while liraglutide (3.0 mg daily) achieved a mean 6.5% reduction. > The most potent agent, tirzepatide (15 mg weekly), showed superior efficacy, resulting in an average weight loss of 20.9% from baseline, significantly outperforming other monotherapy GLP-1 RAs (p<0.001). Common adverse events, primarily gastrointestinal issues like nausea and diarrhea, were more frequent with active treatment compared to placebo, with semaglutide showing a 2.1-fold higher incidence of these events than placebo, though most were mild to moderate and generally led to similar discontinuation rates across agents. Overall, the safety profiles were consistent with known effects of GLP-1 RAs.